Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections

@inproceedings{Gazit2021ComparingSN,
  title={Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections},
  author={Sivan Gazit and Roei Shlezinger and Gloria Perez and Rueben Lotan and Ayelet Peretz and Amir Ben-Tov and Daniel Cohen and Khitam Muhsen and Gabby Chodick and Tal Patalon},
  booktitle={medRxiv},
  year={2021}
}
Background: Reports of waning vaccine-induced immunity against COVID-19 have begun to surface. With that, the comparable long-term protection conferred by previous infection with SARS-CoV-2 remains unclear. Methods: We conducted a retrospective observational study comparing three groups: (1)SARS-CoV-2-naive individuals who received a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine, (2)previously infected individuals who have not been vaccinated, and (3)previously infected and… 
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
TLDR
Two doses of BNT162b2 vaccine were associated with high short-term protection against SARS-CoV-2 infection; this protection waned considerably after 6 months and infection-acquired immunity boosted with vaccination remained high more than 1 year after infection.
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
TLDR
Protection against reinfection decreased as the time increased since the last immunity-conferring event; however, this protection was higher than that conferred after the same time had elapsed since receipt of a second dose of vaccine among previously uninfected persons.
Time to reinfection and vaccine breakthrough SARS-CoV-2 infections: a retrospective cohort study
TLDR
Overall, the risks associated with COVID-19 infection are far greater than the marginal advantages of immunity acquired by prior infection, and both acquired immunities were highly effective in preventing breakthrough and reinfection.
Protective immunity after recovery from SARS-CoV-2 infection
Protection and waning of natural and hybrid COVID-19 immunity
TLDR
Protection from reinfection decreases with time since previous infection, but is, nevertheless, higher than that conferred by vaccination with two doses at a similar time since the last immunity-conferring event.
Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination
TLDR
Estimating protection against Omicron re-infection and hospitalization conferred by prior heterologous SARS-CoV-2 (non-Omicron) infection and/or up to three doses of (ancestral, Wuhan-like) mRNA vaccine found that >2 doses of ancestral Wuhen-like vaccine may be of marginal incremental value to previously-infected individuals.
Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK SIREN prospective cohort study of healthcare workers March 2020 to September 2021
TLDR
Protection from infection-acquired immunity showed evidence of waning in unvaccinated follow-up but remained consistently over 90% in those who received two doses of vaccine, even in those infected over 15-months ago.
Understanding ‘hybrid immunity’: comparison and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines
  • N. Epsi, S. Richard, S. Pollett
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2022
TLDR
Differences between groups were small in magnitude, and these results offer insights into vaccine immunogenicity variations that may help inform vaccination timing strategies.
SARS-CoV-2 Variants, Vaccines, and Host Immunity
TLDR
Both SARS-CoV-2-induced host immune activation and vaccine-induced immune responses are reviewed, highlighting the responses of immune memory cells that are key indicators of host immunity.
Coronavirus Disease 2019 (COVID-19) Vaccine Boosting in Previously Infected or Vaccinated Individuals
TLDR
There is no evidence of an advantage to administering more than 1 dose of vaccine to previously infected persons and boosting protects against Omicron variant infection in those previously infected or vaccinated.
...
...

References

SHOWING 1-10 OF 32 REFERENCES
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
TLDR
It is found that the risk for infection was significantly higher for early vaccinees compared to those vaccinated later, and should prompt further investigagions into long-term protection against different strains, and prospective clinical trials to examine the effect of a booster vaccine against breakthrough infection.
Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021
TLDR
It is suggested that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection.
The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data
  • G. Chodick, L. Tene, K. Muhsen
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2021
TLDR
The effectiveness of the BNT162b2 vaccine in preventing SARS-CoV-2 infection and COVID-19-related hospitalization and mortality is comparable to the one reported in the phase III clinical trial.
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
TLDR
This study examined whether sera from recovered and naïve donors, collected before and after immunizations with existing messenger RNA (mRNA) vaccines, could neutralize the Wuhan-Hu-1 and B.1.
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
TLDR
This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection
TLDR
The data show that SARS-CoV-2 infection induces polyfunctional memory T cells detectable at 12-months post-infection, with higher frequency noted in those who originally experienced severe disease.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
TLDR
It is concluded that memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination and boosting vaccinated individuals with currently available mRNA vaccines would produce a quantitative increase in plasma neutralizing activity but not the qualitative advantage against variants obtained by vaccinating convalescent individuals.
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.
TLDR
The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
TLDR
An overview of the results from pre-clinical studies in animal models as well as clinical studies in humans that assessed the efficacy of SARS-CoV-2 mRNA vaccines are provided, with a primary focus on adaptive immune responses post vaccination.
...
...